Sulopenem etzadroxil/Probenecid

硫培南/丙磺舒

Report date: 2026/04/03 20:03:44

Base Information

Drug NameSulopenem etzadroxil/Probenecid
Drug Alias Name舒洛培南Orlynvah
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome P450 2C9 inhibitorsCell wall inhibitors
TargetsCytochrome P450 2C9
Therapy Area/IndicationsCystitisPyelonephritisUrinary Tract Infections +[4] 
Global Approved IndicationsUrinary Tract Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/10/25
Country/TerritoryUnited States
CombinationsYes Sulopenem etzadroxilProbenecid
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesIterum Therapeutics Us LtdIterum Therapeutics International Ltd
Inactive CompaniesN/A
Active IndicationsCystitisUrinary Tract Infections
Inactive IndicationsPyelonephritisIntraabdominal Infections

Other Information

ATC CodeN/A
Related LinksN/A